

## JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES

### Meeting of the Advisory Committee; Meeting

**AGENCY:** Joint Board for the Enrollment of Actuaries.

**ACTION:** Notice of Federal Advisory Committee meeting.

**SUMMARY:** The Joint Board for the Enrollment of Actuaries gives notice of a teleconference meeting of the Advisory Committee on Actuarial Examinations (a portion of which will be open to the public) on January 6–7, 2022.

**DATES:** Thursday, January 6, 2022, from 9:00 a.m. to 5:00 p.m. (EST), and Friday January 7, 2022, from 8:30 a.m. to 5:00 p.m. (EST).

**ADDRESSES:** The meeting will be held by teleconference.

**FOR FURTHER INFORMATION CONTACT:** Elizabeth Van Osten, Designated Federal Officer, Advisory Committee on Actuarial Examinations, at 202–317–3648 or [elizabeth.j.vanosten@irs.gov](mailto:elizabeth.j.vanosten@irs.gov).

**SUPPLEMENTARY INFORMATION:** Notice is hereby given that the Advisory Committee on Actuarial Examinations will meet by teleconference on Thursday, January 6, 2022, from 9:00 a.m. to 5:00 p.m. (EST), and Friday, January 7, 2022, from 8:30 a.m. to 5:00 p.m. (EST).

The purpose of the meeting is to discuss topics and questions that may be recommended for inclusion on future Joint Board examinations in actuarial mathematics and methodology referred to in 29 U.S.C. 1242(a)(1)(B) and to review the November 2021 Pension (EA–2F) Examination in order to make recommendations relative thereto, including the minimum acceptable pass score. Topics for inclusion on the syllabus for the Joint Board's examination program for the May 2022 Basic (EA–1) Examination and the May 2022 Pension (EA–2L) Examination also will be discussed.

A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. App. 2, that the portions of the meeting dealing with the discussion of questions that may appear on the Joint Board's examinations and the review of the November 2021 Pension (EA–2F) Examination fall within the exceptions to the open meeting requirement set forth in 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such portions be closed to public participation.

The portion of the meeting dealing with the discussion of the other topics

will commence at 1:00 p.m. (EST) on January 6, 2022 and will continue for as long as necessary to complete the discussion, but not beyond 3:00 p.m. (EST). Time permitting, after the close of this discussion by Advisory Committee members, interested persons may make statements germane to this subject. Persons wishing to make oral statements should contact the Designated Federal Officer at [NHQJB EA@IRS.GOV](mailto:NHQJB EA@IRS.GOV) and include the written text or outline of comments they propose to make orally. Such comments will be limited to 10 minutes in length. Persons who wish to attend the public session should contact the Designated Federal Officer at [NHQJB EA@IRS.GOV](mailto:NHQJB EA@IRS.GOV) to obtain teleconference access instructions. Notifications of intent to make an oral statement or to attend the meeting must be sent electronically to the Designated Federal Officer by no later than December 31, 2021. In addition, any interested person may file a written statement for consideration by the Joint Board and the Advisory Committee by sending it to [NHQJB EA@IRS.GOV](mailto:NHQJB EA@IRS.GOV).

Dated: December 2, 2021.

**Thomas V. Curtin,**

*Executive Director, Joint Board for the Enrollment of Actuaries.*

[FR Doc. 2021–26535 Filed 12–7–21; 8:45 am]

**BILLING CODE 4830–01–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Tamika Mayo, M.D.; Decision and Order

On July 23, 2019, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (hereinafter, DEA or Government), issued an Order to Show Cause (hereinafter, OSC) to Tamika Mayo, M.D. (hereinafter, Respondent), of Baton Rouge, Louisiana. Request for Final Agency Action (hereinafter, RFAA), Exhibit (hereinafter RFAAX) A (OSC), at 1 and 5. The OSC proposed to revoke Respondent's DEA Certificate of Registration, Control No. BM7946835 and to deny any pending applications for a new registration or for renewal pursuant to 21 U.S.C. 824(a)(4) and 823(f), because Respondent had “committed acts which render [her] registration inconsistent with the public interest.” *Id.* at 1.

The OSC alleged that Respondent had issued thousands of prescriptions for controlled substances in Louisiana during periods when her Louisiana Controlled Dangerous Substance

(hereinafter, CDS) license was expired. *Id.* at 2–3. Specifically, the OSC alleged that between September 1, 2016, and January 17, 2017, Respondent issued over 1,850 prescriptions for controlled substances while her CDS license was expired; between September 1, 2017, and June 13, 2018, Respondent issued over 1,730 prescriptions for controlled substances while her CDS license was expired; and between September 1, 2018, and February 15, 2019, Respondent issued over 400 prescriptions for controlled substances while her CDS license was expired. *Id.* According to the OSC, because Respondent was not authorized to issue prescriptions for controlled substances during these periods, the prescriptions were issued in violation of state and federal law. *Id.* at 3 (citing La. Stat. §§ 40:967(A)(1)(a) & 40:973; La. Admin. Code tit. 46, §§ 2705 & 2707(B)(3)–(4); 21 U.S.C. 841(a)(1); 21 CFR 1306.03 & 1306.04). The OSC concluded that “[b]y issuing more than 3,900 prescriptions for controlled substances without state authorization, and therefore in violation of state and federal law, [Respondent has] committed such acts as would render [her] continued registration inconsistent with the public interest.” *Id.* (citing 21 U.S.C. 824(a)(4) & 823(f)(2) & (4)).

The OSC notified Respondent of the right to request a hearing on the allegations or to submit a written statement, while waiving the right to a hearing, the procedures for electing each option, and the consequences for failing to elect either option. *Id.* at 4 (citing 21 CFR 1301.43). The OSC also notified Respondent of the opportunity to submit a corrective action plan. *Id.* at 4–5 (citing 21 U.S.C. 824(c)(2)(C)).

By letter dated August 17, 2019, Respondent offered an explanation in response to the allegations and stated that she was “not waving [sic] [her] right to a hearing.” RFAAX B. On August 20, 2019, Administrative Law Judge Mark M. Dowd (hereinafter, the ALJ) issued an Order Directing Clarification, in which the ALJ instructed Respondent, if she was seeking a hearing, to “submit a document affirmatively and unconditionally requesting a hearing” and stated that if the new document was timely filed, the initial filing would be deemed a timely hearing request. RFAAX C, at 3. By email dated August 27, 2019, Respondent requested a hearing. RFAAX D. On August 28, 2019, the ALJ issued an Order for Prehearing Statements. RFAAX E, at 1. The Government timely filed its prehearing statement on September 9, 2019. *Id.* at 2. On September 30, 2019, the ALJ